查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008840

重組DNA技術市場報告：按產品、組件、應用、最終用戶和地區分類（2026-2034年）

Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球重組DNA技術市場規模達8,272億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到11862億美元，2026年至2034年的複合年成長率（CAGR）為3.63%。市場成長的主要促進因素包括基因工程和生物技術的持續進步、生物製藥需求的成長、個人化醫療的加速發展以及慢性病盛行率的上升。

重組DNA技術市場趨勢：

生物製藥需求不斷成長

對單株抗體、疫苗和胰島素等生物製藥產品的需求不斷成長是推動市場發展的主要動力。例如，根據IMARC統計，2023年全球生物製藥市場規模達3,005億美元。展望未來，IMARC Group預測，到2032年，市場規模將達到6,439億美元，2024年至2032年的複合年成長率（CAGR）為8.6%。重組DNA技術在這些產品的生產中發揮著至關重要的作用，而這些產品對於治療各種慢性疾病至關重要。預計這些因素將在未來幾年推動重組DNA技術市場的發展。

慢性病盛行率增加

癌症、糖尿病和心血管疾病等慢性病盛行率的不斷上升是推動市場成長的關鍵因素。例如，根據國際糖尿病聯盟（IDF）發布的《糖尿病地圖集》（2021年），20至79歲成年人中，糖尿病盛行率為10.5%。此外，到2045年，每八個人中就有一人（約7.83億人）將患有糖尿病，增幅高達46%。重組DNA技術能夠生產重要的治療性蛋白質和激素，例如用於糖尿病管理的胰島素和用於治療貧血的促紅血球生成素。這些因素進一步積極影響重組DNA技術產業市場。

技術進步

持續的技術創新，例如 CRISPR 和其他基因編輯工具，正在提高重組 DNA 技術的精確性和適用性，從而推動市場擴張。例如，2024 年 8 月，一群德國研究人員開發了一種改進的 CRISPR（叢集規律間隔短回文重複序列）技術，旨在解決和改善 CAR-T 細胞療法在治療血液腫瘤和固體癌方面面臨的挑戰。 CRISPR 是一項獨特的技術，它使遺傳學家和醫學研究人員能夠透過移除、插入或替換 DNA 序列來編輯基因組的某些部分，從而提升重組 DNA 技術系統市場的收入。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球重組DNA技術市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 醫學領域
    • 主要部分
      • 治療藥物
      • 人類蛋白質
      • 疫苗
  • 非醫療
    • 主要部分
      • 生物技術作物
      • 特種化學品
      • 其他

第7章 市場區隔：依組件分類

  • Expression System
  • 克隆載體

第8章 市場區隔：依應用領域分類

  • 食品和農業
  • 健康與疾病
  • 環境
  • 其他

第9章 市場區隔：依最終用戶分類

  • 生物技術和製藥公司
  • 學術和政府附屬研究機構
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc
    • Cibus
    • F.Hoffmann-La Roche Ltd
    • GenScript
    • GlaxoSmithKline plc.
    • Horizon Discovery Group plc
    • Merck KGaA
    • New England Biolabs
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi SA
    • Syngene International Ltd（Biocon Limited）
Product Code: SR112026A4484

The global recombinant DNA technology market size reached USD 827.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 1,186.2 Billion by 2034, exhibiting a growth rate (CAGR) of 3.63% during 2026-2034. The ongoing advancements in genetic engineering and biotechnology, the growing demand for biopharmaceuticals, increasing shift towards personalized medicines, and the rising prevalence of chronic diseases are primarily driving the market's growth.

RECOMBINANT DNA TECHNOLOGY MARKET ANALYSIS:

  • Major Market Drivers: The rising demand for improving different health conditions coupled with the improving treatment strategies on account of the developing diagnostics kits, monitoring devices, and new therapeutic approaches, represents one of the key factors impelling the growth of the market.
  • Key Market Trends: Rapid urbanization, growing global population, reducing arable land, considerable rising food shortage, and increasing adoption of GMO crops, are escalating the market demand. In addition, the integration of recombinant DNA technology with effective gene therapy for replacing defective genes with normal ones and the production of antigen-specific antibodies for clinical research, studies, and disease diagnosis, are anticipated to drive the market growth in the upcoming years.
  • Competitive Landscape: Some of the prominent recombinant DNA technology market companies include Amgen Inc, Cibus, F.Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline plc., Horizon Discovery Group plc, Merck KGaA, New England Biolabs, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A, and Syngene International Ltd (Biocon Limited), among many others.
  • Geographical Trends: According to the recombinant DNA technology market dynamics, North America holds a prominent share in the recombinant DNA technology market, driven by extensive research and development activities, well-established healthcare infrastructure, and significant government funding. Moreover, the growth in Europe is supported by a strong focus on research and development and high adoption of biopharmaceuticals .
  • Challenges and Opportunities: Rising regulatory compliances and high competition among key players are hampering the market growth. However, there is an increasing demand for environmentally friendly and fuel-efficient landing gear systems. Manufacturers can capitalize on this trend by developing lightweight materials and energy-efficient designs.

RECOMBINANT DNA TECHNOLOGY MARKET TRENDS:

Rising Demand for Biopharmaceuticals

The rising demand for biopharmaceuticals, including monoclonal antibodies , vaccines, and insulin, is a major driver. For instance, according to IMARC, the global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. Recombinant DNA technology is pivotal in the production of these products, which are essential for treating various chronic diseases. These factors are expected to propel the recombinant DNA technology market in the coming years.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is one of the significant factors driving the market's growth. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 suffer from diabetes. Also, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Recombinant DNA technology enables the production of essential therapeutic proteins and hormones, such as insulin for diabetes management and erythropoietin for anemia treatment. These factors are further positively influencing the recombinant DNA technology industry market.

Technological Advancements

Continuous technological innovations, such as CRISPR and other gene-editing tools, are enhancing the precision and application scope of recombinant DNA technology, driving the market expansion. For instance, in August 2024, a group of German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors. CRISPR is a unique technology that enables geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences, thereby boosting the recombinant DNA technology systems market revenue.

GLOBAL RECOMBINANT DNA TECHNOLOGY INDUSTRY SEGMENTATION:

Breakup by Product:

  • Medical
    • Therapeutic Agent
    • Human Protein
    • Vaccines
  • Non-Medical
    • Biotech Crops
    • Specialty Chemicals
    • Others

According to the recombinant DNA technology market outlook, recombinant DNA technology enables the development of gene therapies to treat genetic disorders like cystic fibrosis, hemophilia, and muscular dystrophy. This technology has revolutionized the production of human insulin, making it more accessible for diabetic patients. While crops like Bt cotton, Roundup Ready soybeans, and Golden Rice have been developed using rDNA technology to enhance resistance to pests, herbicides, and to improve nutritional content.

Breakup by Component:

  • Expression System
  • Cloning Vector

According to the recombinant DNA technology market overview, an expression system refers to the host organism and the molecular machinery used to produce recombinant proteins. It includes the host cells, the vectors, and the regulatory sequences necessary for gene expression. While a cloning vector is a DNA molecule used to carry foreign genetic material into a host cell, where it can be replicated and/or expressed. It is used in the development of genetically modified crops with desirable traits such as pest resistance and improved nutritional content.

Breakup by Application:

  • Food and Agriculture
  • Health and Disease
  • Environment

Recombinant DNA technology is used to develop genetically modified (GM) crops with desirable traits such as increased yield, pest resistance, herbicide tolerance, and improved nutritional content. This is crucial for meeting the food demands of a growing global population. Apart from this, in health and disease, it enables the production of insulin, growth hormones, monoclonal antibodies, and vaccines. The demand for effective and affordable biopharmaceuticals drives this sector. Besides this, it is also used to engineer microorganisms that can break down pollutants and toxins in the environment. This helps in cleaning up oil spills, heavy metals, and other environmental contaminants.

Breakup by End User:

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes

In biotechnology and pharmaceutical companies, recombinant DNA technology is used to produce human insulin in bacteria, which is a major advancement over previous methods using animal insulin. Companies use rDNA to develop monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. While government research institutes like the CDC use rDNA technology to monitor and study pathogens, enabling rapid response to outbreaks and epidemics.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the recombinant DNA technology market statistics, North America is one of the prominent regions for rDNA technology due to significant investments in biotechnology and pharmaceuticals. Moreover, Europe has a well-established biotechnology sector, particularly in countries like Germany, France, and the UK. The growth of the European region is driven by the strong collaboration between academic institutions, research institutes, and industry.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Amgen Inc
  • Cibus
  • F.Hoffmann-La Roche Ltd
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • New England Biolabs
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A
  • Syngene International Ltd (Biocon Limited)

()

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global recombinant DNA technology market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global recombinant DNA technology market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global recombinant DNA technology market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Recombinant DNA Technology Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Medical
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Therapeutic Agent
      • 6.1.2.2 Human Protein
      • 6.1.2.3 Vaccines
    • 6.1.3 Market Forecast
  • 6.2 Non-Medical
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Biotech Crops
      • 6.2.2.2 Specialty Chemicals
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Component

  • 7.1 Expression System
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cloning Vector
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Food and Agriculture
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Health and Disease
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Environment
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Biotechnology and Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Government Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Cibus
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 F.Hoffmann-La Roche Ltd
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 GenScript
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 GlaxoSmithKline plc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Horizon Discovery Group plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 New England Biolabs
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Novo Nordisk A/S
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi S.A
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Syngene International Ltd (Biocon Limited)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Recombinant DNA Technology Market: Major Drivers and Challenges
  • Figure 2: Global: Recombinant DNA Technology Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Recombinant DNA Technology Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Recombinant DNA Technology Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Recombinant DNA Technology Market: Breakup by Component (in %), 2025
  • Figure 6: Global: Recombinant DNA Technology Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Recombinant DNA Technology Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Recombinant DNA Technology Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Recombinant DNA Technology (Medical) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Recombinant DNA Technology (Medical) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Recombinant DNA Technology (Non-Medical) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Recombinant DNA Technology (Non-Medical) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Recombinant DNA Technology (Expression System) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Recombinant DNA Technology (Expression System) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Recombinant DNA Technology (Cloning Vector) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Recombinant DNA Technology (Cloning Vector) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Recombinant DNA Technology (Food and Agriculture) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Recombinant DNA Technology (Food and Agriculture) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Recombinant DNA Technology (Health and Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Recombinant DNA Technology (Health and Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Recombinant DNA Technology (Environment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Recombinant DNA Technology (Environment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Recombinant DNA Technology (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Recombinant DNA Technology (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Recombinant DNA Technology (Biotechnology and Pharmaceutical Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Recombinant DNA Technology (Biotechnology and Pharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Recombinant DNA Technology (Academic and Government Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Recombinant DNA Technology (Academic and Government Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Recombinant DNA Technology (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Recombinant DNA Technology (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: North America: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Asia-Pacific: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Asia-Pacific: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: China: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: China: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Japan: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Japan: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: India: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: India: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: South Korea: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: South Korea: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Australia: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Australia: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Indonesia: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Indonesia: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Others: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Europe: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Europe: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Germany: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Germany: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: France: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: France: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: United Kingdom: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: United Kingdom: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Italy: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Italy: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Spain: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Spain: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Russia: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Russia: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Latin America: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Latin America: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Brazil: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Brazil: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Mexico: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Mexico: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Middle East and Africa: Recombinant DNA Technology Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Middle East and Africa: Recombinant DNA Technology Market: Breakup by Country (in %), 2025
  • Figure 79: Middle East and Africa: Recombinant DNA Technology Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Global: Recombinant DNA Technology Industry: SWOT Analysis
  • Figure 81: Global: Recombinant DNA Technology Industry: Value Chain Analysis
  • Figure 82: Global: Recombinant DNA Technology Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Recombinant DNA Technology Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Recombinant DNA Technology Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Recombinant DNA Technology Market Forecast: Breakup by Component (in Million USD), 2026-2034
  • Table 4: Global: Recombinant DNA Technology Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Recombinant DNA Technology Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Recombinant DNA Technology Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Recombinant DNA Technology Market: Competitive Structure
  • Table 8: Global: Recombinant DNA Technology Market: Key Players